<DOC>
	<DOCNO>NCT02571218</DOCNO>
	<brief_summary>In study , investigator aim identify characterize , mean EnSite Velocity Research Software , electrophysiological characteristic substrate sustain AF patient persistent AF test whether ablation patient-specific substrate might improve acute long-term success conventional catheter ablation therapy .</brief_summary>
	<brief_title>AF Substrate Mapping Guided Ablation</brief_title>
	<detailed_description>This study prospective , single center , randomize , single-blind , control , 2-arm parallel group trial Milan , Italy . The total duration study expect 24 month ~12 month enrollment . Approximately 80 subject suffer persistent AF randomize 1:1 fashion follow investigation arm : - Modified circumferential pulmonary vein ablation alone ( mCPVA ) ; - Substrate-targeted ablation guide AF substrate mapping , follow completion modify circumferential pulmonary vein ablation ( Substrate+ mCPVA ) - Ablate area fast regular electrical activity , start fast cycle length ( define Mean CL range 120-250 millisecond , SD CL range 1-30 millisecond - Ablate area consistent rotational focal propagation pattern ( define conduction velocity vector ) - Ablate area comprise slow conduction zone possible arrhythmia circuit - If AF terminate RF ablation , stimulation protocol use examine AF re-inducible . If AF sustain re-inducible physician decides remap , map perform substrate-targeted ablation . If AF re-inducible , mCPVA complete Subjects follow 3 , 6 , 12 month . The primary objective study ass acute long-term outcome patient-tailored substrate-targeted ablation ( Substrate ) plus modified circumferential pulmonary vein ablation ( Substrate+mCPVA ) versus modify circumferential pulmonary vein ablation alone ( mCPVA ) . The secondary objective study map characterize electrophysiological substrate AF , include regular fast activity , complex fractionate electrograms , wave front propagation direction , fibrosis .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>18 85 year age Persistent AF schedule undergo catheter ablation approve standard indication ESC/EHRA guideline First second time ablation persistent AF Ability provide write informed consent study participation willing able comply study evaluation follow schedule Had two previous AF ablation procedure Secondary AF Hyperthyroidism Left ventricular ejection fraction &lt; 30 % NYHA functional class IV Left atrial area &gt; 35 cm2 Uncorrected severe valvular heart disease Contraindication anticoagulation Presence leave atrial thrombus Recent ( &lt; 6 Months ) myocardial Infarction unstable angina coronary artery bypass Thoracic surgery congenital , valvular aortic disease History cerebrovascular accident Pregnancy Significant comorbidities cancer , severe renal insufficiency require hemodialysis , severe obstructive lung disease , cirrhosis , life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>mapping</keyword>
	<keyword>substrate</keyword>
	<keyword>ablation</keyword>
</DOC>